

To compare the pain relief from combined intrathecal bupivacaine-morphine with bupivacaine alone in lower limb surgery

Submission date 25/04/2022	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 12/05/2022	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 05/05/2022	Condition category Surgery	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol

Background and study aims

Inadequate pain medication during and after surgery may lead to long term pain after surgery.

This study was designed to ascertain the effect of morphine addition to bupivacaine in the management of postoperative pain in patients undergoing lower limb surgeries at the Tamale Teaching Hospital, Ghana.

Who can participate?

Patients aged 16 – 60 years, undergoing lower limb surgery.

What does the study involve?

Participants will be randomly allocated to receive bupivacaine alone or bupivacaine plus morphine during surgery. Follow up lasts 72 hours.

What are the possible benefits and risks of participating?

Benefits: There were no immediate benefits for participation in the study. No gifts or money were given in exchange for the information obtained. However, data generated from this study will help policy makers in the Ministry of Health to improve the management of postoperative pain after Orthopaedic and Trauma surgeries.

Risks: Participants were informed that they may experience slight pain during the sample collection process. Should they suffer any injury during the collection process, members of the research team will take full responsibility and cover all expenses pertaining to treatment.

Where is the study run from?

Tamale Teaching Hospital, Ghana.

When is the study starting and how long is it expected to run for?

April 2021 to November 2021

Who is funding the study?
Investigator initiated and funded

Who is the main contact?
Sylvanus Kampo, sylvanuskampo@yahoo.com
Fidelis Bayor, bayorfidelis@gmail.com

Contact information

Type(s)
Scientific

Contact name
Mr Fidelis Bayor

ORCID ID
<http://orcid.org/0000-0002-2703-8856>

Contact details
University of Ghana Medical School
Accra
Ghana
24
+233 249229949
bayorfidelis@gmail.com

Type(s)
Principal Investigator

Contact name
Dr Sylvanus Kampo

Contact details
CK Tedam University of Technology and Applied Sciences
Navrongo
Ghana
19
+233 559355229
sylvanuskampo@yahoo.com

Additional identifiers

EudraCT/CTIS number
Nil known

IRAS number

ClinicalTrials.gov number
Nil known

Secondary identifying numbers

Nil known

Study information

Scientific Title

Analgesic efficiency of intrathecal bupivacaine with morphine and bupivacaine alone in lower limb orthopaedic surgery. A comparative study

Acronym

IBM

Study objectives

Bupivacaine with morphine induces better postoperative pain relief and improve patient outcomes in lower limb orthopaedic surgery

Ethics approval required

Old ethics approval format

Ethics approval(s)

Approved 30/09/2021, Ethical review board of the Kwame Nkrumah University of Science and Technology (University Post Office, Kumasi, Ghana; +233(0)205453785; chrpe@knust.edu.gh), ref: CHRPE/AP/416/21

Study design

Randomised comparative controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

No participant information sheet available

Health condition(s) or problem(s) studied

Postoperative pain management in trauma patients

Interventions

After meeting the inclusion criteria, eligible patients received 15 mg preservative free hyperbaric bupivacaine and 0.2 mg morphine or 15 mg bupivacaine alone. Patients were followed up 72 hrs for postoperative complications and patient outcome.

Each recruited patient was randomly assigned to one of two groups using a computer-generated

random number table. Group A (n=30) represented those who received bupivacaine alone and Group B (n=30) represented those who received bupivacaine with morphine.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

bupivacaine, morphine

Primary outcome measure

1. Vital signs (pulse rate, blood pressure, oxygen saturation, and respiratory rate) of the patient were monitored and recorded for every 5 minutes for the first 30 minutes and then for every 15 minutes during surgery
2. Pain severity was measured every 4 hours for 72 hours immediately after the surgery on a 100-mm VAS, 0 mm = no pain, and 100 mm = intolerable pain.

Secondary outcome measures

1. The episodes of postoperative nausea and vomiting (PONV) were identified by direct scheduled assessments or by a spontaneous complaint by the patients after the surgery. The incidence of PONV was recorded hourly for the first 4 hours and then 4 hourly for the next 24 hours using a 3 point ordinal scale (0 = none, 1 = nausea, 2 = vomiting). The incidence of PONV was calculated and categorized as early (0 – 4 hours) or delayed (5 – 24hours).
2. The incidence of pruritus was recorded every 4 hours for 48 hours after surgery on a four-point categorical scale as; 0 = no pruritus, 1 = mild, 2 = moderate, 3 = severe pruritus.
3. Overall perioperative satisfaction was evaluated on the day of discharged during an interview as; 4 = excellent, 3 = good, 2 = satisfactory, 1 = poor.

Overall study start date

01/04/2021

Completion date

30/11/2021

Eligibility

Key inclusion criteria

1. Patients undergoing elective lower limb orthopaedic surgery
2. ASA status class I and II
3. Patients between 16 - 60 years of age
4. Patients who were on admission for 72 hours or more postoperatively

Participant type(s)

Patient

Age group

Adult

Sex

Both

Target number of participants

150

Total final enrolment

60

Key exclusion criteria

1. Pregnant or breastfeeding mothers
2. Patients with polytrauma
3. Glasgow coma scale <15
4. Opioids abusers
5. Expected post-surgical stay <24 hours
6. ASA physical status class III and IV
7. Patients allergic to bupivacaine and/morphine
8. Contraindication to spinal anaesthesia

Date of first enrolment

10/09/2021

Date of final enrolment

29/11/2021

Locations**Countries of recruitment**

Ghana

Study participating centre

Tamale Teaching Hospital

Box 1350TL

Tamale

Ghana

-

Sponsor information**Organisation**

Platinum Orthopaedic and Spine Clinic

Sponsor details

Korle Bu Teaching Hospital

University of Ghana Medical School

Accra
Ghana
24
+233 249229949
abuunaaim@yahoo.co.uk

Sponsor type

University/education

Funder(s)

Funder type

Other

Funder Name

Investigator initiated and funded

Results and Publications

Publication and dissemination plan

Study results will be presented at anaesthesia conferences in Ghana and planned publication will be made in a high-impact peer-reviewed journal

Intention to publish date

31/07/2022

Individual participant data (IPD) sharing plan

Availability of data and materials: The datasets generated and/or analysed during the current study are not publicly available due to patient confidentiality but are available from the corresponding author on reasonable request.

sylvanuskampo@yahoo.com

IPD sharing plan summary

Available on request